Difference between revisions of "Acute myeloid leukemia, FLT3-positive - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Clinical Trial Registry] Awaiting publication" to "Awaiting publication") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.clinicaltrials.gov/ct2/show/[https://clinicaltrials.gov/ct2/show/" to "https://www.clinicaltrials.gov/ct2/show/") |
||
| Line 47: | Line 47: | ||
| style="background-color:#d73027" |Inferior RFS | | style="background-color:#d73027" |Inferior RFS | ||
|- | |- | ||
| − | |[https://www. | + | |[https://www.clinicaltrials.gov/ct2/show/NCT02997202 Awaiting publication (2215-CL-0304)] |
|2017-ongoing | |2017-ongoing | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
Revision as of 19:57, 2 June 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main FLT3+ AML page for current regimens.
Maintenance after upfront therapy, including allogeneic HSCT
Observation
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Xuan et al. 2020 (Sorafenib-Flt3 AML-2015) | 2015-2018 | Phase 3 (C) | Sorafenib | Inferior 1-year cumulative incidence of relapse |
Preceding treatment
References
- Sorafenib-Flt3 AML-2015: Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, Luo X, Shi P, Liu H, Wang Z, Jiang L, Yu C, Zhou X, Lin R, Chen Y, Tu S, Huang X, Liu Q. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1201-1212. Epub 2020 Aug 10. link to original article PubMed Clinical Trial Registry
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Burchert et al. 2020 (SORMAIN) | 2010-2016 | Phase 3 (C) | Sorafenib | Inferior RFS |
| Awaiting publication (2215-CL-0304) | 2017-ongoing | Phase 3 (C) | Gilteritinib | In progress |
Preceding treatment
References
- SORMAIN: Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020 Sep 10;38(26):2993-3002. Epub 2020 Jul 16. link to original article contains dosing details in manuscript PubMed Link to clinical trial registration DRKS00000591
- 2215-CL-0304: Clinical Trial Registry